Loading news...
Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF, AIM:SEI) said it has provided MI 61-101 disclosure related to its completed acquisition of Challenger Energy...
The biotechnology sector’s strong fundamentals and robust innovation could continue to drive outperformance this year, according to Baird analysts. The firm...
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless disease If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless disease
Alzheimer’s disease (AD) has for decades been one of the most stubborn challenges in neuroscience and drug development. Regulatory successes like Biogen Inc...
Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.
Biogen Inc. shares, despite retail investor pessimism, rose 15.1% in 2025. Besides the successful launch of Leqembi, I highlight Skyclarys, an Nrf2 activator for the treatment of Friedreich's ataxia, as a driver of Biogen's EBIT growth. Its sales totaled $132.9 million in Q3, up 29.9% year-over-year.
Assenagon Asset Management S.A. cut its position in Biogen Inc. (NASDAQ: BIIB) by 36.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,913 shares of the biotechnology company's stock after selling 4,023 shares during the period. Assenagon Asset Management
Thrivent Financial for Lutherans grew its position in shares of Biogen Inc. (NASDAQ: BIIB) by 24.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,195 shares of the biotechnology company's stock after buying an additional 3,544 shares during the
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results from the completed Phase 3 VALOR study and its open-label extension (OLE) study evaluating QALSODY® (tofersen) for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) with over 3.5 years of follow-up. These results show that early initiation of QALSODY was associated with numerically slower decline in measures of clinical function, breathing and strength, as well as reduction in the risk of death or permanent ventilation. Sustained reductions in neurofilament, a marker of neurodegeneration, further validate the clinical results and demonstrate QALSODY's impact on the underlying biology of SOD1-ALS.
Corient Private Wealth LLC boosted its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 15.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,331 shares of the biotechnology company's stock after acquiring an additional 4,540 shares during the quarter.
The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, effective December 22, 2025.
Balyasny Asset Management L.P. raised its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 5.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 831,905 shares of the biotechnology company's stock after purchasing an additional 45,686 shares during
Daiwa Securities Group Inc. lessened its holdings in Biogen Inc. (NASDAQ: BIIB) by 9.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,128 shares of the biotechnology company's stock after selling 4,265 shares during the quarter. Daiwa Securities Group Inc.'s holdings
Federated Hermes Inc. raised its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 16.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 120,277 shares of the biotechnology company's stock after purchasing an additional 17,069 shares during the quarter. Federated
Pre-Market Stock Futures: Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of 2025, and the odds still heavily favor a 25-basis-point rate hike. The worry hanging over traders is that many fear a "hawkish rate cut." Where they do cut 25 basis... Here Are Wednesday's Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More.
TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, 14-day oral single course treatment for women with PPD. This first-of-its-kind treatment offers relief from depressive symptoms, with benefits seen in clinical studies as early as day 3, significant reduction of symptoms by th.
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China.
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life—
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society (AES).
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started treatment at an early stage